 |
Ability Pharmaceuticals |
ABTL1014 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Leukaemia and Lymphomas |
2RP |
|
ABTL1014
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
|
Ability Pharmaceuticals |
ABTL0815 |
Biodrugs/ Drugs |
Cancer |
Solid Tumors |
1NRP |
|
ABTL0815
Therapeutic area:
Cancer
|
|
Ability Pharmaceuticals |
ABTL0812 |
Biodrugs/ Drugs |
Cancer |
Lung, Endometrial and Pancreatic Cancer |
4PhII |
|
ABTL0812
Therapeutic area:
Cancer
|
 |
Almirall |
ADP12734 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Psoriasis |
3PhI |
|
ADP12734
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
Almirall |
Tildrakizumab |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Psoriasis |
6Reg. |
|
Tildrakizumab
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
Almirall |
ALM12701 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Psoriasis |
2RP |
|
ALM12701
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
Almirall |
P3058 |
Biodrugs/ Drugs |
Dermatology |
Onychomycosis |
5PhIII |
|
P3058
Therapeutic area:
Dermatology
|
|
Almirall |
ALM14712 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Atopic dermatits |
2RP |
|
ALM14712
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
Almirall |
ALM14801 |
Biodrugs/ Drugs |
Dermatology |
Acne |
2RP |
|
ALM14801
Therapeutic area:
Dermatology
|
|
Almirall |
P3074 |
Biodrugs/ Drugs |
Dermatology |
Androgenetic Alopecia |
5PhIII |
|
P3074
Therapeutic area:
Dermatology
|
|
Almirall |
KX2-391 |
Biodrugs/ Drugs |
Dermatology |
Actinic keratosis |
5PhIII |
|
KX2-391
Therapeutic area:
Dermatology
|
 |
Aptatargets |
ApTOLL-01 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Central Nervous System |
Acute ischemic stroke
Acute coronary syndrome |
3PhI |
|
ApTOLL-01
Therapeutic area:
Cardiovascular and circulatory systems
Central Nervous System
|
|
Aptatargets |
ApTOLL-03 |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Multiple Sclerosis |
1NRP |
|
ApTOLL-03
Therapeutic area:
Autoimmune & Inflammation
|
 |
APTUS Biotech |
AptaMnk |
Biodrugs/ Drugs |
Cancer |
Breast Cancer |
1NRP |
|
AptaMnk
Therapeutic area:
Cancer
|
 |
Araclon Biotech |
ABvac40 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's Disease |
4PhII |
|
ABvac40
Therapeutic area:
Central Nervous System
|
 |
Archivel Farma |
RUTI |
Vaccines |
Cancer |
Bladder cancer. |
3PhI |
|
RUTI
Therapeutic area:
Cancer
|
|
Archivel Farma |
RUTI® |
Vaccines |
Infections |
Active tuberculosis - Latent Tuberculosis |
4PhII |
Europe and South Africa |
RUTI®
Therapeutic area:
Infections
|
 |
ASCIL Biopharm |
APOC new treatment for NET and Acromegaly |
Biodrugs/ Drugs |
Cancer |
APOC is a new drug product containing octreotide, the best in class somatostatin analogue (SSA) and the cornerstone of therapy for patients with Neuroendocrine Tumors (NETs) and acromegaly. ASCIL is selecting partner(s) for pivotal phase III studies. |
4PhII |
|
APOC new treatment for NET and Acromegaly
Therapeutic area:
Cancer
|
|
ASCIL Biopharm |
ONYMED for nail diseases |
Biodrugs/ Drugs |
Dermatology |
ONYMED is an innovative long acting technology platform designed to provide a safer and more efficient way to treat or prevent nail disorders and diseases. ONYMED allows to reduce dramatically the dose and the frequency of treatment. Ready for licensing. |
3PhI |
|
ONYMED for nail diseases
Therapeutic area:
Dermatology
|
 |
ATRYS HEALTH |
NILO1 |
Biodrugs/ Drugs |
Cancer
Central Nervous System |
Brain tumor and brain lesions |
1NRP |
Spain |
NILO1
Therapeutic area:
Cancer
Central Nervous System
|
 |
Bioibérica |
Droglican |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Symptomatic treatment of knee osteoarthritis |
6Reg. |
Spain |
Droglican
Therapeutic area:
Musculoskeletal Disorders
|
|
Bioibérica |
BIS014 |
Biodrugs/ Drugs |
Analgesia & Pain
Central Nervous System |
Neuropathic pain |
2RP |
Europe |
BIS014
Therapeutic area:
Analgesia & Pain
Central Nervous System
|
|
Bioibérica |
Cartisorb |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Symptomatic treatment of osteoarthritis |
6Reg. |
Spain |
Cartisorb
Therapeutic area:
Musculoskeletal Disorders
|
|
Bioibérica |
Duartron |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Alleviation of mild to moderate osteoarthritis of the knee |
6Reg. |
|
Duartron
Therapeutic area:
Musculoskeletal Disorders
|
|
Bioibérica |
Hialsorb intra-articular injection |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Indicated for treatment of degenerative or mechanical joint diseases |
6Reg. |
Spain |
Hialsorb intra-articular injection
Therapeutic area:
Musculoskeletal Disorders
|
|
Bioibérica |
Condrosan |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Symptomatic treatment of osteoarthritis |
6Reg. |
Spain |
Condrosan
Therapeutic area:
Musculoskeletal Disorders
|
 |
Bioncotech Therapeutics |
BO-112 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
3PhI |
|
BO-112
Therapeutic area:
Cancer
|
 |
Bionure |
BN201 |
Biodrugs/ Drugs |
Central Nervous System
Ophthalmology and optometry |
Acute Optic Neuritis, Neuromyelitis Optica, Multiple Sclerosis |
3PhI |
|
BN201
Therapeutic area:
Central Nervous System
Ophthalmology and optometry
|
 |
DIOMUNE SL |
IV1303 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections |
Sepsis treatment, Stroke, Rare diseases (CDH), Leishmania, ZIKV |
2RP |
|
IV1303
Therapeutic area:
Autoimmune & Inflammation
Cardiovascular and circulatory systems
Genetic Diseases and Dysmorphic syndromes
Infections
|
 |
ENTRECHEM |
Brasilicardin analogs |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Immunosupression |
1NRP |
|
Brasilicardin analogs
Therapeutic area:
Autoimmune & Inflammation
|
|
ENTRECHEM |
EC-8042 iv for liposarcoma |
Biodrugs/ Drugs |
Cancer |
liposarcoma myxoide |
2RP |
|
EC-8042 iv for liposarcoma
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-8042 iv for Ewing sarcoma |
Biodrugs/ Drugs |
Cancer |
Solid tumours |
2RP |
|
EC-8042 iv for Ewing sarcoma
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-70124 po for AML |
Biodrugs/ Drugs |
Cancer |
Acute myeloid leukemia |
2RP |
|
EC-70124 po for AML
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-8042 iv for Triple negative breast cancer |
Biodrugs/ Drugs |
Cancer |
Triple negative breast cancer |
2RP |
|
EC-8042 iv for Triple negative breast cancer
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-70124 po for TNBC |
Biodrugs/ Drugs |
Cancer |
Triple negative breast cancer |
2RP |
|
EC-70124 po for TNBC
Therapeutic area:
Cancer
|
|
ENTRECHEM |
EC-70124 po for prostate cancer |
Biodrugs/ Drugs |
Cancer |
Castration resistant prostate cancer |
2RP |
|
EC-70124 po for prostate cancer
Therapeutic area:
Cancer
|
 |
ESTEVE |
MUMO1 |
Biodrugs/ Drugs |
Analgesia & Pain |
Acute and chronic, moderate to severe pain |
2RP |
|
MUMO1
Therapeutic area:
Analgesia & Pain
|
|
ESTEVE |
EGT-301 |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Hunter syndrome: Lysosomal storage disease |
1NRP |
|
EGT-301
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
ESTEVE |
EGT-201 |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Sanfilippo B syndrome: Lisosomal storage rare disease |
1NRP |
|
EGT-201
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
ESTEVE |
E-52862 |
Biodrugs/ Drugs |
Analgesia & Pain |
Neuropathic Pain |
4PhII |
|
E-52862
Therapeutic area:
Analgesia & Pain
|
|
ESTEVE |
EGT-101 |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Sanfilippo A syndrome:Lysosomal storage rare disease |
2RP |
|
EGT-101
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
ESTEVE |
E-58425 |
Biodrugs/ Drugs |
Analgesia & Pain |
Acute and chronic, moderate to severe pain |
5PhIII |
|
E-58425
Therapeutic area:
Analgesia & Pain
|
 |
FECYT |
p38 |
Biodrugs/ Drugs |
Analgesia & Pain
Central Nervous System |
Neuropathic Pain |
2RP |
|
p38
Therapeutic area:
Analgesia & Pain
Central Nervous System
|
|
FECYT |
Pylori |
Biodrugs/ Drugs |
Infections |
H. pylori |
2RP |
|
Pylori
Therapeutic area:
Infections
|
 |
FERRER |
FAB-120 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Diabetic Retinopathy |
2RP |
|
FAB-120
Therapeutic area:
Ophthalmology and optometry
|
|
FERRER |
FAB-117 |
Gene / Cell Therapy |
Central Nervous System |
Spinal Cord Injury |
4PhII |
|
FAB-117
Therapeutic area:
Central Nervous System
|
|
FERRER |
SP1440 |
Biodrugs/ Drugs |
Central Nervous System |
Small Molecular. Schizophrenia and cognitive improvement |
2RP |
|
SP1440
Therapeutic area:
Central Nervous System
|
 |
FUND. PROGRESO Y SALUD |
FIBAO-13007 |
Gene / Cell Therapy |
Cancer |
Cancer cells |
2RP |
|
FIBAO-13007
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
CABIMER-11 New target gene and delivery systems for the Treatment of Retinitis Pigmentosa |
Gene / Cell Therapy |
Ophthalmology and optometry |
Retinitis pigmentosa |
1NRP |
|
CABIMER-11 New target gene and delivery systems for the Treatment of Retinitis Pigmentosa
Therapeutic area:
Ophthalmology and optometry
|
|
FUND. PROGRESO Y SALUD |
Allogeneic Adipose Mesenchymal stem cells / Allodepleted Bone Marrow Progenitors |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Blood and Lymphatic systems |
Chronic Graft versus Host Disease, Haematological Malignancies |
4PhII |
|
Allogeneic Adipose Mesenchymal stem cells / Allodepleted Bone Marrow Progenitors
Therapeutic area:
Autoimmune & Inflammation
Blood and Lymphatic systems
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-99 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Nanoemulsions for the treatment of obesity |
2RP |
|
FIMABIS-99
Therapeutic area:
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD |
CABIMER-13003 |
Vaccines |
Central Nervous System |
Parkinson |
1NRP |
|
CABIMER-13003
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-13001 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Treatment and/or Prevention of Non-alcoholic fatty liver disease (NAFLD) |
2RP |
|
FIMABIS-13001
Therapeutic area:
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD |
Engineered Corneas |
Gene / Cell Therapy |
Ophthalmology and optometry |
Corneal ulcers |
4PhII |
|
Engineered Corneas
Therapeutic area:
Ophthalmology and optometry
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-77 |
Biodrugs/ Drugs |
Central Nervous System |
Hydroxytyrosol ethers |
2RP |
|
FIMABIS-77
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
CABIMER-14001 Condon plasma factors for skin regeneration |
Gene / Cell Therapy |
Autoimmune & Inflammation
Dermatology |
Dermatitis |
1NRP |
|
CABIMER-14001 Condon plasma factors for skin regeneration
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
|
FUND. PROGRESO Y SALUD |
FIBICO-14003 |
Gene / Cell Therapy |
Musculoskeletal Disorders |
Musculoskeletal disorders |
1NRP |
|
FIBICO-14003
Therapeutic area:
Musculoskeletal Disorders
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-13007 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Treatment and/or prevention of metabolic and cardiovascular diseases |
2RP |
|
FIMABIS-13007
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD |
Autologous Bone Marrow progenitors, Adipose and Bone Marrow Mesenchymal stem cells |
Gene / Cell Therapy |
Autoimmune & Inflammation
Central Nervous System |
Stroke, Multiple Sclerosis and ALS |
4PhII |
|
Autologous Bone Marrow progenitors, Adipose and Bone Marrow Mesenchymal stem cells
Therapeutic area:
Autoimmune & Inflammation
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
FIBICO-14002 |
Biodrugs/ Drugs |
Cancer |
Metastatic processes and resistant cancers |
1NRP |
|
FIBICO-14002
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
Autologous Bone Marrow Mononuclear cells and Adipose Mesenchymal stem cells |
Gene / Cell Therapy |
Digestive System |
Extended Liver resection, Faecal Incontinence |
4PhII |
|
Autologous Bone Marrow Mononuclear cells and Adipose Mesenchymal stem cells
Therapeutic area:
Digestive System
|
|
FUND. PROGRESO Y SALUD |
FISEVI-14012 |
Biodrugs/ Drugs |
Infections |
Multirresistant infections |
2RP |
|
FISEVI-14012
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD |
Autologous Bone Marrow Mononuclear cells |
Gene / Cell Therapy |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Acute Myocardial Infarction/Dilated Myocardiopathy/Chronic Ischemic Cardiopathy/Critical Limb Ischemia in diabetic & non patients |
4PhII |
|
Autologous Bone Marrow Mononuclear cells
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD |
FISEVI-13007 |
Gene / Cell Therapy |
Cancer |
Hepatocarcinoma |
2RP |
|
FISEVI-13007
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
FIMABIS-14003 |
Biodrugs/ Drugs |
Dermatology
Infections |
Treatment of mucocutaneous herpes infections |
4PhII |
|
FIMABIS-14003
Therapeutic area:
Dermatology
Infections
|
|
FUND. PROGRESO Y SALUD |
FRM-5 |
Gene / Cell Therapy |
Others |
Transplant |
2RP |
|
FRM-5
Therapeutic area:
Others
|
|
FUND. PROGRESO Y SALUD |
FISEVI-13020 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease |
2RP |
|
FISEVI-13020
Therapeutic area:
Central Nervous System
|
|
FUND. PROGRESO Y SALUD |
FIBAO-13014 Combination of Ketamine and Meperidine |
Biodrugs/ Drugs |
Autoimmune & Inflammation |
Mucositis |
3PhI |
|
FIBAO-13014 Combination of Ketamine and Meperidine
Therapeutic area:
Autoimmune & Inflammation
|
|
FUND. PROGRESO Y SALUD |
FISEVI 141 |
Biodrugs/ Drugs |
Infections |
Sepsis, Acute lung injury |
2RP |
|
FISEVI 141
Therapeutic area:
Infections
|
|
FUND. PROGRESO Y SALUD |
FIBAO-116 |
Biodrugs/ Drugs |
Analgesia & Pain |
Fibromyalgia |
3PhI |
|
FIBAO-116
Therapeutic area:
Analgesia & Pain
|
|
FUND. PROGRESO Y SALUD |
FISEVI-13002 |
Biodrugs/ Drugs |
Cancer |
Multiple myeloma |
2RP |
|
FISEVI-13002
Therapeutic area:
Cancer
|
|
FUND. PROGRESO Y SALUD |
Autologous Bone Marrow Mononuclear cells |
Gene / Cell Therapy |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Critical Limb Ischemia in diabetic patients |
3PhI |
|
Autologous Bone Marrow Mononuclear cells
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
FUND. PROGRESO Y SALUD |
FISEVI-121 |
Gene / Cell Therapy |
Autoimmune & Inflammation |
Transplant |
2RP |
|
FISEVI-121
Therapeutic area:
Autoimmune & Inflammation
|
|
FUND. PROGRESO Y SALUD |
FIBAO-91 Melatonine Solution |
Biodrugs/ Drugs |
Infections |
Sepsis |
4PhII |
|
FIBAO-91 Melatonine Solution
Therapeutic area:
Infections
|
 |
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Advanced cell therapies |
Gene / Cell Therapy |
Ophthalmology and optometry |
Eye rare diseases |
4PhII |
Spain / Europe |
Advanced cell therapies
Therapeutic area:
Ophthalmology and optometry
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
New generation of peptides |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Blood and Lymphatic systems
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
Ophthalmology and optometry |
Chronic complications of Diabetes / Choric kidney disease |
2RP |
|
New generation of peptides
Therapeutic area:
Autoimmune & Inflammation
Blood and Lymphatic systems
Cardiovascular and circulatory systems
Kidney and Genitourinary system
Metabolic / Endocrinology
Ophthalmology and optometry
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Peptide derived from a natural compound |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Metabolic / Endocrinology |
Osteoporosis treatment |
1NRP |
|
Peptide derived from a natural compound
Therapeutic area:
Autoimmune & Inflammation
Metabolic / Endocrinology
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Advanced cell therapies |
Gene / Cell Therapy |
Blood and Lymphatic systems
Cancer |
Oncology / Haematological disorders |
3PhI |
Spain / US |
Advanced cell therapies
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
|
FUNDACIÓN JIMÉNEZ DÍAZ (Instituto de Investigación Sanitaria) |
Mutli-target siRNA approach |
Gene / Cell Therapy |
Autoimmune & Inflammation
Kidney and Genitourinary system |
Chronic Kidney Disease (CKD)/ Akute Kidney Injury (AKI) |
2RP |
|
Mutli-target siRNA approach
Therapeutic area:
Autoimmune & Inflammation
Kidney and Genitourinary system
|
 |
Fundacion MEDINA |
MDN-018 |
Biodrugs/ Drugs |
Infections |
Fungal Infections |
1NRP |
|
MDN-018
Therapeutic area:
Infections
|
|
Fundacion MEDINA |
MDN-057/MDN-058/MDN-059 |
Biodrugs/ Drugs |
Infections |
Gram negative infections |
1NRP |
|
MDN-057/MDN-058/MDN-059
Therapeutic area:
Infections
|
|
Fundacion MEDINA |
MDN-0090 |
Biodrugs/ Drugs |
Cancer |
Pancreatic Cancer |
1NRP |
|
MDN-0090
Therapeutic area:
Cancer
|
|
Fundacion MEDINA |
MDN-0109, MDN-110, MDN-111, MDN- 112 |
Biodrugs/ Drugs |
Infections |
Malaria |
1NRP |
|
MDN-0109, MDN-110, MDN-111, MDN- 112
Therapeutic area:
Infections
|
|
Fundacion MEDINA |
MDN-0145; MDN-0146 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson |
1NRP |
|
MDN-0145; MDN-0146
Therapeutic area:
Central Nervous System
|
|
Fundacion MEDINA |
MDN-0147; MDN-0148 & MDN-0149 |
Biodrugs/ Drugs |
Cancer |
Melanoma |
1NRP |
|
MDN-0147; MDN-0148 & MDN-0149
Therapeutic area:
Cancer
|
|
Fundacion MEDINA |
MDN-005 |
Biodrugs/ Drugs |
Central Nervous System
Musculoskeletal Disorders |
Amyotrophic lateral sclerosis (ALS) |
1NRP |
|
MDN-005
Therapeutic area:
Central Nervous System
Musculoskeletal Disorders
|
|
Fundacion MEDINA |
MDN-088 |
Biodrugs/ Drugs |
Cancer |
Breast, Colon & Lung Cancer |
1NRP |
|
MDN-088
Therapeutic area:
Cancer
|
 |
Genmedica Therapeutics |
GMC-252 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Type 2 Diabetes |
3PhI |
Europe |
GMC-252
Therapeutic area:
Metabolic / Endocrinology
|
 |
GP-PHARM |
Lutrate Depot 22,5 mg |
Biodrugs/ Drugs |
Cancer |
Prostate Cancer |
6Reg. |
|
Lutrate Depot 22,5 mg
Therapeutic area:
Cancer
|
|
GP-PHARM |
Triptorelina Depot 1-3 |
Biodrugs/ Drugs |
Cancer |
Prostate Cancer |
3PhI |
|
Triptorelina Depot 1-3
Therapeutic area:
Cancer
|
|
GP-PHARM |
Desmopresina Solution |
Biodrugs/ Drugs |
Kidney and Genitourinary system |
Nocturnal Enuresis |
6Reg. |
|
Desmopresina Solution
Therapeutic area:
Kidney and Genitourinary system
|
|
GP-PHARM |
Lutrate Depot 45 mg |
Biodrugs/ Drugs |
Cancer |
Prostate Cancer |
3PhI |
Worldwide |
Lutrate Depot 45 mg
Therapeutic area:
Cancer
|
|
GP-PHARM |
TERIPERATIDE |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Osteoporosis |
3PhI |
|
TERIPERATIDE
Therapeutic area:
Musculoskeletal Disorders
|
|
GP-PHARM |
Pegylated Liposomes for Oncology |
Biodrugs/ Drugs |
Cancer |
Advanced Ovarian Cancer, Advanced Breast Cancer |
3PhI |
Worldwide |
Pegylated Liposomes for Oncology
Therapeutic area:
Cancer
|
|
GP-PHARM |
depot form. |
Biodrugs/ Drugs |
Cancer |
Several |
3PhI |
|
depot form.
Therapeutic area:
Cancer
|
|
GP-PHARM |
Octeotride LAR |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Acromegaly |
4PhII |
Worldwide |
Octeotride LAR
Therapeutic area:
Metabolic / Endocrinology
|
 |
Histocell |
HR016 |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Acute Lung Injury |
3PhI |
|
HR016
Therapeutic area:
Respiratory and Pulmonary system
|
|
Histocell |
HC016 |
Biodrugs/ Drugs |
Central Nervous System |
Acute Spinal Cord Injury |
4PhII |
|
HC016
Therapeutic area:
Central Nervous System
|
|
Histocell |
HR004 |
Biodrugs/ Drugs |
Musculoskeletal Disorders |
Bone Regeneration |
4PhII |
|
HR004
Therapeutic area:
Musculoskeletal Disorders
|
 |
IIS La Fe |
Mutant of candida albicans and use in therapy against candidiasis |
Biodrugs/ Drugs |
Infections |
Mutant of candida albicans and use in therapy against candidiasis |
1NRP |
|
Mutant of candida albicans and use in therapy against candidiasis
Therapeutic area:
Infections
|
 |
Institut Quimic de Sarrià (IQS) |
Chondro-implant |
Gene / Cell Therapy |
Cardiovascular and circulatory systems |
Bioactive implant for myocardial regeneration, ventricular support and elliptical shape restoration. Acute Cartilage Injure |
1NRP |
|
Chondro-implant
Therapeutic area:
Cardiovascular and circulatory systems
|
|
Institut Quimic de Sarrià (IQS) |
Cardio-implant |
Gene / Cell Therapy |
Cardiovascular and circulatory systems |
PCL (Polycaprolactone), SAP (self-assembling peptide) bioactive and biomimetic scaffolds for cartilage regeneration. Heart infarct |
1NRP |
|
Cardio-implant
Therapeutic area:
Cardiovascular and circulatory systems
|
 |
Iproteos |
IPR-179 |
Biodrugs/ Drugs |
Central Nervous System |
Epilepsy |
1NRP |
|
IPR-179
Therapeutic area:
Central Nervous System
|
|
Iproteos |
IPR-166 |
Biodrugs/ Drugs |
Central Nervous System |
Cognitive Impairment associated to neurodegenerative and psychiatric diseases (schizophrenia, Parkinson's disease) |
2RP |
Spain |
IPR-166
Therapeutic area:
Central Nervous System
|
 |
IRYCIS |
New compound for the treatment of isquemical stroke |
Biodrugs/ Drugs |
Central Nervous System |
Isquemic stroke |
1NRP |
Spain |
New compound for the treatment of isquemical stroke
Therapeutic area:
Central Nervous System
|
 |
Leukos Biotech |
LK-01 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
AML |
3PhI |
|
LK-01
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
 |
Lipopharma Therapeutics |
LP30171 |
Biodrugs/ Drugs |
Cancer
Metabolic / Endocrinology |
Metabolic Diseases, cancer |
1NRP |
|
LP30171
Therapeutic area:
Cancer
Metabolic / Endocrinology
|
|
Lipopharma Therapeutics |
LP205A1 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology |
Cardiovascular and Metabolic Diseases, CNS, |
1NRP |
|
LP205A1
Therapeutic area:
Cardiovascular and circulatory systems
Central Nervous System
Metabolic / Endocrinology
|
|
Lipopharma Therapeutics |
LPA181 |
Biodrugs/ Drugs |
Central Nervous System |
Spinal Cord Injury, Pain. Global rigths outlicensed to a third party biotech company |
2RP |
|
LPA181
Therapeutic area:
Central Nervous System
|
|
Lipopharma Therapeutics |
LP226A1 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's Disease |
2RP |
|
LP226A1
Therapeutic area:
Central Nervous System
|
|
Lipopharma Therapeutics |
LP204A1 |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Cardiovascular and circulatory systems |
Inflammation, Cardiovascular |
1NRP |
|
LP204A1
Therapeutic area:
Autoimmune & Inflammation
Cardiovascular and circulatory systems
|
|
Lipopharma Therapeutics |
LP561A1 |
Biodrugs/ Drugs |
Cancer |
Glioma and other solid tumours |
4PhII |
|
LP561A1
Therapeutic area:
Cancer
|
 |
Minoryx |
MIN-102 |
Biodrugs/ Drugs |
Central Nervous System |
Friedreich's Ataxia |
4PhII |
|
MIN-102
Therapeutic area:
Central Nervous System
|
|
Minoryx |
MIN-102 |
Biodrugs/ Drugs |
Central Nervous System
Metabolic / Endocrinology |
X-linked Adrenoleukodystrophy |
5PhIII |
|
MIN-102
Therapeutic area:
Central Nervous System
Metabolic / Endocrinology
|
 |
NATAC |
Retriacyl |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retinitis Pigmentosa |
5PhIII |
Europe |
Retriacyl
Therapeutic area:
Ophthalmology and optometry
|
 |
Neurofix |
NFX91 |
Biodrugs/ Drugs |
Others |
Sleep disorders |
1NRP |
|
NFX91
Therapeutic area:
Others
|
|
Neurofix |
NFX88 |
Biodrugs/ Drugs |
Analgesia & Pain
Central Nervous System |
Neuropathic pain |
4PhII |
Spain |
NFX88
Therapeutic area:
Analgesia & Pain
Central Nervous System
|
|
Neurofix |
NFX81 |
Biodrugs/ Drugs |
Central Nervous System |
Spinal Cord Injuries |
2RP |
Spain |
NFX81
Therapeutic area:
Central Nervous System
|
 |
nLife Therapeutics, S.L. |
NLF-PD-1233 |
Biodrugs/ Drugs |
Central Nervous System |
Parkinson Disease |
2RP |
Europe and USA |
NLF-PD-1233
Therapeutic area:
Central Nervous System
|
 |
Oryzon |
OG-new series in KDM |
Biodrugs/ Drugs |
Cancer
Others |
Solid cancers, Oncohaematology |
1NRP |
|
OG-new series in KDM
Therapeutic area:
Cancer
Others
|
|
Oryzon |
ORY-2001 |
Biodrugs/ Drugs |
Central Nervous System |
CNS Basket Trial Aggression |
4PhII |
|
ORY-2001
Therapeutic area:
Central Nervous System
|
|
Oryzon |
ORY-2001 |
Biodrugs/ Drugs |
Central Nervous System |
Alzheimer's disease (Mild Moderate) |
4PhII |
|
ORY-2001
Therapeutic area:
Central Nervous System
|
|
Oryzon |
ORY-1001 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Cancer |
Acute myeloid leukemia (AML) |
4PhII |
|
ORY-1001
Therapeutic area:
Blood and Lymphatic systems
Cancer
|
|
Oryzon |
ORY-2001 |
Biodrugs/ Drugs |
Central Nervous System |
Multiple Sclerosis (Relapse Remitting & Secondary Progressive) |
4PhII |
|
ORY-2001
Therapeutic area:
Central Nervous System
|
|
Oryzon |
ORY-1001 |
Biodrugs/ Drugs |
Cancer |
Small-cell lung cancer |
4PhII |
|
ORY-1001
Therapeutic area:
Cancer
|
|
Oryzon |
ORY-1001 |
Biodrugs/ Drugs |
Cancer |
Small-cell lung cancer |
4PhII |
|
ORY-1001
Therapeutic area:
Cancer
|
|
Oryzon |
ORY-3001 |
Biodrugs/ Drugs |
Others |
Non-oncological disease |
2RP |
|
ORY-3001
Therapeutic area:
Others
|
 |
PaloBiofarma |
PBF-1129 |
Biodrugs/ Drugs |
Cancer |
Lung Cancer |
3PhI |
Spain |
PBF-1129
Therapeutic area:
Cancer
|
|
PaloBiofarma |
PBF-677 |
Biodrugs/ Drugs |
Digestive System |
Colitis |
4PhII |
Spain |
PBF-677
Therapeutic area:
Digestive System
|
|
PaloBiofarma |
PBF-999 |
Biodrugs/ Drugs |
Cancer |
Solid Tumors |
3PhI |
Spain |
PBF-999
Therapeutic area:
Cancer
|
|
PaloBiofarma |
PBF-509 |
Biodrugs/ Drugs |
Cancer
Central Nervous System |
Lung Cancer |
4PhII |
Spain |
PBF-509
Therapeutic area:
Cancer
Central Nervous System
|
|
PaloBiofarma |
PBF680 |
Biodrugs/ Drugs |
Respiratory and Pulmonary system |
Asthma |
4PhII |
Spain |
PBF680
Therapeutic area:
Respiratory and Pulmonary system
|
 |
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Ewing Sarcoma |
4PhII |
EU & NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
TRABECTEDIN + Radiotherapy |
Biodrugs/ Drugs |
Cancer |
Sarcoma |
4PhII |
Europe |
TRABECTEDIN + Radiotherapy
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
4PhII |
EU & NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) + DOXORUBICIN |
Biodrugs/ Drugs |
Cancer |
Small Cell lung cancer |
5PhIII |
EU , LA & LATAM |
LURBINECTEDIN (PM1183) + DOXORUBICIN
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Endometrial cancer |
4PhII |
EU & NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
TRABECTEDIN + PLD |
Biodrugs/ Drugs |
Cancer |
Ovarian Cancer. |
5PhIII |
Europe |
TRABECTEDIN + PLD
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
BRCA+Breast Cancer |
4PhII |
|
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) + CPT 11 |
Biodrugs/ Drugs |
Cancer |
Solid Tumors |
4PhII |
|
LURBINECTEDIN (PM1183) + CPT 11
Therapeutic area:
Cancer
|
|
PharmaMar |
TRABECTEDIN |
Biodrugs/ Drugs |
Cancer |
Retroperitoneal L-Sarcoma |
4PhII |
Italy |
TRABECTEDIN
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Mesothelioma |
4PhII |
|
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
PM184 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
3PhI |
EU & NA |
PM184
Therapeutic area:
Cancer
|
|
PharmaMar |
PM14 |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
3PhI |
EU |
PM14
Therapeutic area:
Cancer
|
|
PharmaMar |
TRABECTEDIN + PLD |
Biodrugs/ Drugs |
Cancer |
Ovarian cancer (Japan) |
3PhI |
Japan |
TRABECTEDIN + PLD
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Solid tumors |
3PhI |
Japan |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
|
PharmaMar |
LURBINECTEDIN (PM1183) |
Biodrugs/ Drugs |
Cancer |
Small Cell Lung Cancer |
4PhII |
EU & NA |
LURBINECTEDIN (PM1183)
Therapeutic area:
Cancer
|
 |
PRAXIS |
EPIPROT |
Biodrugs/ Drugs |
Dermatology |
Diabetic Foot |
5PhIII |
|
EPIPROT
Therapeutic area:
Dermatology
|
|
PRAXIS |
TERARMET |
Biodrugs/ Drugs |
Others |
SANFILIPPO |
1NRP |
|
TERARMET
Therapeutic area:
Others
|
|
PRAXIS |
NNE |
Biodrugs/ Drugs |
Dermatology |
Diabetic Foot |
1NRP |
|
NNE
Therapeutic area:
Dermatology
|
|
PRAXIS |
NANOPLATFORMM |
Biodrugs/ Drugs |
Infections |
NANOFORMULATION OF DRUGS FOR RESISTANT INFECTIONS |
1NRP |
|
NANOPLATFORMM
Therapeutic area:
Infections
|
|
PRAXIS |
Nanoantibiotics |
Gene / Cell Therapy |
Respiratory and Pulmonary system |
Resistent Infections (Cystic Fibrosis) |
1NRP |
|
Nanoantibiotics
Therapeutic area:
Respiratory and Pulmonary system
|
|
PRAXIS |
NANOENZHIMES |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
SANFILIPPO/FABRY |
1NRP |
|
NANOENZHIMES
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
PRAXIS |
NANOCANTHER |
Biodrugs/ Drugs |
Cancer |
THERAPY SYSTEMS FOR PANCREATIC CANCER |
1NRP |
|
NANOCANTHER
Therapeutic area:
Cancer
|
|
PRAXIS |
CLINGLIO |
Biodrugs/ Drugs |
Cancer |
Glioma |
4PhII |
|
CLINGLIO
Therapeutic area:
Cancer
|
|
PRAXIS |
TAT-CF |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
CYSTIC FIBROSIS |
1NRP |
|
TAT-CF
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
PRAXIS |
BERENICE |
Biodrugs/ Drugs |
Genetic Diseases and Dysmorphic syndromes |
Chagas |
5PhIII |
|
BERENICE
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
PRAXIS |
ANTIAGE |
Biodrugs/ Drugs |
Dermatology |
ANTIAGING DRUGS AND NUTRACEUTICS |
1NRP |
|
ANTIAGE
Therapeutic area:
Dermatology
|
|
PRAXIS |
TERFIQEC |
Gene / Cell Therapy |
Genetic Diseases and Dysmorphic syndromes |
Cystic Fibrosis |
2RP |
|
TERFIQEC
Therapeutic area:
Genetic Diseases and Dysmorphic syndromes
|
|
PRAXIS |
ATEROLESS |
Biodrugs/ Drugs |
Dermatology |
ANTIAGING COSMETIC AND NUTRACEUTICS |
1NRP |
|
ATEROLESS
Therapeutic area:
Dermatology
|
|
PRAXIS |
PROHEAL |
Biodrugs/ Drugs |
Dermatology |
Bioactive wound dressings (Diabetic / vascular) |
1NRP |
|
PROHEAL
Therapeutic area:
Dermatology
|
|
PRAXIS |
IGRALZHEIMER |
Biodrugs/ Drugs |
Central Nervous System |
ALZHEIMER |
1NRP |
|
IGRALZHEIMER
Therapeutic area:
Central Nervous System
|
 |
REIG JOFRE |
P0265 |
Biodrugs/ Drugs |
Dermatology |
Skin infections |
5PhIII |
Spain, Mexico |
P0265
Therapeutic area:
Dermatology
|
|
REIG JOFRE |
P0223 |
Biodrugs/ Drugs |
Dermatology |
Skin infection |
6Reg. |
Spain |
P0223
Therapeutic area:
Dermatology
|
 |
Sanifit |
SNF472 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Calciphylaxis (dialysis) |
4PhII |
|
SNF472
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
|
Sanifit |
SNF472 |
Biodrugs/ Drugs |
Cardiovascular and circulatory systems
Metabolic / Endocrinology |
Cardiovascular disease (dialysis) |
4PhII |
|
SNF472
Therapeutic area:
Cardiovascular and circulatory systems
Metabolic / Endocrinology
|
 |
SOM Biotech |
SOM3355 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Huntington's disease, Tourette syndrome and Tardive Dyskinesia |
4PhII |
|
SOM3355
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
|
SOM Biotech |
SOM1201 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Adrenoleukodystrophy |
4PhII |
|
SOM1201
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
|
SOM Biotech |
SOM0208 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology |
Niemann-Pick |
1NRP |
|
SOM0208
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
|
|
SOM Biotech |
SOM1202 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes |
Adrenomyeloneuropathy |
1NRP |
|
SOM1202
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
|
|
SOM Biotech |
SOM1311 |
Biodrugs/ Drugs |
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology |
Phenylketonuria |
1NRP |
|
SOM1311
Therapeutic area:
Central Nervous System
Genetic Diseases and Dysmorphic syndromes
Metabolic / Endocrinology
|
 |
Sylentis |
Tivanisirán / SYL1001 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Dry Eye Syndrome |
5PhIII |
|
Tivanisirán / SYL1001
Therapeutic area:
Ophthalmology and optometry
|
|
Sylentis |
Bamosiran / SYL040012 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Ocular Hypertension, Glaucoma |
4PhII |
|
Bamosiran / SYL040012
Therapeutic area:
Ophthalmology and optometry
|
|
Sylentis |
siRNA / SYL116011 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Ocular Allergy |
2RP |
|
siRNA / SYL116011
Therapeutic area:
Ophthalmology and optometry
|
|
Sylentis |
siRNA / SYL1801 |
Biodrugs/ Drugs |
Ophthalmology and optometry |
Retina |
2RP |
|
siRNA / SYL1801
Therapeutic area:
Ophthalmology and optometry
|
 |
Thrombotargets |
TT-173 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Haemorrhage |
5PhIII |
|
TT-173
Therapeutic area:
Blood and Lymphatic systems
|
|
Thrombotargets |
TT-112 |
Biodrugs/ Drugs |
Blood and Lymphatic systems |
Antifibrinolysis |
1NRP |
|
TT-112
Therapeutic area:
Blood and Lymphatic systems
|
 |
VCN Biosciences |
VCN-02 |
Gene / Cell Therapy |
Cancer |
Solid Tumors |
1NRP |
|
VCN-02
Therapeutic area:
Cancer
|
|
VCN Biosciences |
VCN-01 |
Gene / Cell Therapy |
Cancer |
Pancreatic cancer |
3PhI |
|
VCN-01
Therapeutic area:
Cancer
|
|
VCN Biosciences |
VCN-11 |
Gene / Cell Therapy |
Cancer |
Solid Tumors |
2RP |
|
VCN-11
Therapeutic area:
Cancer
|
|
VCN Biosciences |
VCN-01 |
Gene / Cell Therapy |
Cancer |
Head & Neck Cancer |
3PhI |
|
VCN-01
Therapeutic area:
Cancer
|
|
VCN Biosciences |
VCN-01 |
Gene / Cell Therapy |
Cancer |
Retinoblastoma |
3PhI |
|
VCN-01
Therapeutic area:
Cancer
|
 |
VENTER PHARMA |
LacTEST 0,45 g |
Biodrugs/ Drugs |
Digestive System |
Evaluation of hypolactasia |
6Reg. |
|
LacTEST 0,45 g
Therapeutic area:
Digestive System
|
|
VENTER PHARMA |
LacTEST 2,7 g |
Biodrugs/ Drugs |
Digestive System |
Evaluation of hypolactasia |
5PhIII |
|
LacTEST 2,7 g
Therapeutic area:
Digestive System
|
 |
Vivia Biotech |
Vivia 009 |
Biodrugs/ Drugs |
Blood and Lymphatic systems
Central Nervous System |
Non Hodgkin Lymphoma, CNS |
2RP |
Europe |
Vivia 009
Therapeutic area:
Blood and Lymphatic systems
Central Nervous System
|
|
Vivia Biotech |
Vivia 011 |
Biodrugs/ Drugs |
Metabolic / Endocrinology |
Obesity, Diabetes |
1NRP |
|
Vivia 011
Therapeutic area:
Metabolic / Endocrinology
|
 |
Vytrus Biotech |
PhyPsor |
Biodrugs/ Drugs |
Autoimmune & Inflammation
Dermatology |
Psoriasis |
1NRP |
|
PhyPsor
Therapeutic area:
Autoimmune & Inflammation
Dermatology
|
 |
ZENDAL |
MTBVAC |
Vaccines |
Infections
Respiratory and Pulmonary system |
MTBVAC is a live freeze dried vaccine based on a genetically attenuated strain of a clinical isolate of M. tuberculosis manufactured by BIOFABRI. MTBVAC is now in Phase 2a in newborns infants and a Phase2a in BCG-vaccinated adults in South Africa |
4PhII |
|
MTBVAC
Therapeutic area:
Infections
Respiratory and Pulmonary system
|